Haematologica Reports

Corporate Symposium

Tumor lysis syndrome: pathogenesis and clinical aspects
Tosi P

Nephrological complications of tumor lysis syndrome
Santoro A, Sestigiani E

The management of tumor lysis syndrome in adult patients with haematological malignancies
Cimino G, Martelli M

Tumor lysis syndrome: prevention and treatment therapeutic guide lines aieop
Prete A, Pession A

Plenary Session I

Molecular pathogenesis

Retinoid acid-inducible gene rig-i is an essential negative regulator of myelopoiesis
Zhu J, Shen S-H, Chen L-J, Sun Y-P, Huang Q-H, Zhang N-N, Kong H, Wang L, Sun Y-W, Zhou G-B,
Chen S-J, Chen Z, Wang Z-G

Analysis of global gene expression in models of acute promyelocytic leukemia and transcriptional
modifications in response to retinoic acid therapy
Alcalay M

Acute promyelocytic leukemia, a model for oncogene-targeted combination therapy
de Thé H, Zhu J, Lallemand-Breitenbach V, Guillemin M-C, Zhou J, Vitoux D

Two decades of cancer genetics: from specificity to pleiotropic networks
Pandolfi PP

Plenary Session II

Molecular targeting of transcription in acute promyelocytic leukemia and beyond

Molecular targeting of retinoic acid receptor activities in acute myeloid leukemia
Zelent A

Molecular targeting of fusion proteins/corepressors interactions: effects on differentiation response and
gene-specific chromatin alterations
Racanicchi S, Billi M, Passeri D, Panigada M, Grignani F

Epigenetic targets of retinoic acid action in acute promyelocytic leukemia
Nervi C

Corporate Symposium

Strategies for advanced apl: long-term followup of arsence therapy and new approaches
Tallman MS

Arsenic trioxide in relapsed acute promyelocytic leukemia: treatment strategies and future prospects
Lengfelder E


Simultaneous Workshops

Workshop I - The acute promyelocytic leukemia associated coagulopathy

Procoagulant surface of leukemic blasts
Brenner B, Nadir Y, Dally N

Retinoic acid modulation of systemic and cellular hemostasis activation
Falanga A

Oral Communications


Workshop II - In vitro and in vivo models

Retinoic acid-dependent gene transactivation by pml-rar· without direct dna-binding
van Wageningen S, Nigten J, Breems-de Ridder MC, Nikoloski G, Erpelinck-Verschueren CAJ, Löwenberg B,


Targeting p73-p53aip1 apoptotic pathway in acute promyelocytic leukemia cells
Lunghi P, Costanzo A, Salvatore L, Noguera N, Tabilio A, Lo Coco F, Levrero M, Bonati A

Oral communications

Poster Session

I - Biology and characterization studies

II - Clinical studies

Plenary Session IV

Other molecular targets in acute promyelocytic leukemia and beyond

Murine models of apl induced by co-expression of the pml-rara fusion with either flt3-itd or oncogenic k-ras alleles
Chan I, Wojiski S, Gilliland DG

Role of the sumo pathway in cellular senescence and development
Bischof O, Nacerddine K, Schwamborn K, Bhaumik M, Artus J, Pandolfi PP, Dejean A

New insights into the transcription repression by pml-rara: involvement of n-cor/smrt-tblr1-hdac3 complex
Tomita A, Naoe T

Plenary Session V

Front-line clinical trials

Role of maintenance treatment after the intensive consolidation program of the original aida protocol
Avvisati G

Trials in acute promyelocytic leukemia: the mrc experience
Burnett AK

Use of atra and arsenic trioxide without chemotherapy (low-risk patients), or with only induction chemotherapy (mylotarg) (high-risk patients) in untreated acute promyelocytic leukemia
Estey E

Arsenic trioxide in relapsed acute promyelocytic leukemia: treatment strategies and future prospects
Lengfelder E

A randomized study with or without maintenance/intensification chemotherapy in newly diagnosed patients with acute promyelocytic leukemia: the jalsg apl97 study
Naoe T, Asou N, Ohno R for the Japan Adult Leukemia Study Group (JALSG)

Risk-adapted treatment of acute promyelocytic leukemia: updated results of the spanish pethema trials using atra and anthracycline monochemotherapy
Sanz MA

Emerging therapeutic strategies in acute promyelocytic leukemia: will less be more?
Tallman MS

Simultaneous Workshops

Workshop III - Minimal residual disease

Minimal residual disease monitoring in acute promyelocytic leukemia: unresolved issues in 2005
Gallagher R, Schachter-Tokarz E, Liao K, Jones D, Estey E

Use of real-time pcr to predict relapse in acute promyelocytic leukemia: the uk experience
Grimwade D

Oral communications

Workshop IV - Therapy of acute promyelocytic leukemia relapse

Oral communications

Plenary Session VI

Management of acute promyelocytic leukemia in developing countries

Epidemiological observations on a specific molecularly-defined subtype of acute myeloid leukemia
Douer D

International consortium for the clinical management of acute promyelocytic leukemia: a pilot project
Löwenberg B

International networking strategies for the management of acute promyelocytic leukemia in developing countries
Ribeiro RC, Razzouk B

Development of the ic-apl project in brazil
Rego EM